KPTI vs NVS
KPTI: Karyopharm is a clinical-stage oncology company commercializing XPOVIO, a first-in-class XPO1 inhibitor for multiple myeloma, with ongoing trials in myelofibrosis and endometrial cancer. NVS: Global pharmaceutical and biotechnology company pioneering disease-modifying treatments across oncology, immunology, neuroscience, and rare genetic diseases.
Side-by-side fundamentals
| Metric | KPTI | NVS | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $7.18 | $153.08 | |
| Market cap as of 2026-07-23 | $178M | $229.2B | |
| P/E as of 2026-07-23 | n/a | 22.11 | |
| PEG as of 2026-07-23 | -0.04 | 3.66 | KPTI lower |
| Net margin as of 2026-07-23 | -129.0% | +22.5% | NVS higher |
| Gross margin as of 2026-07-23 | +96.0% | +75.0% | KPTI higher |
| Operating margin as of 2026-07-23 | -97.0% | +29.9% | NVS higher |
| ROE as of 2026-07-23 | -182.4% | +29.9% | NVS higher |
| ROA as of 2026-07-23 | -176.9% | +11.1% | NVS higher |
| Debt / equity as of 2026-07-23 | 3.78 | 1.18 | NVS lower |
| Revenue growth (YoY) as of 2026-07-23 | +6.3% | +3.3% | KPTI higher |
| Revenue CAGR (3y) SEC XBRL | -2.4% | n/a | |
| Dividend yield as of 2026-07-23 | n/a | +3.0% | |
| Beta as of 2026-07-23 | 0.89 | 1.17 | |
| 1-year return as of 2026-07-22 close | +84.6% | +35.8% | KPTI higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.